Discovery of novel synthetic IL-1 adjuvants

承包商将确定可用于增强人类疫苗效力的新型候选佐剂。在该奖项下进行的研究将有助于新佐剂的管道，导致：（a）利用先天免疫系统的天然能力，以启动和维持有效的T和B细胞反应，并诱导长期免疫记忆，或（B）直接作用于适应性免疫系统的细胞，以增强其对病原体衍生抗原的反应。 研究包括在相关动物模型中用实验性或FDA批准的预防性或治疗性疫苗测试佐剂候选物，以确定疫苗针对与人类疾病相关的一种或多种病原体的潜在功效。

The contractor will identify novel adjuvant candidates that can be used to augment the efficacy of human vaccines. Research performed under this award will contribute to the pipeline of new adjuvant leads that either: (a) exploit the natural capacity of the innate immune system to initiate and sustain effective T and B cell responses and to induce long term immune memory, or (b) act directly on cells of the adaptive immune system to enhance their response to pathogen-derived antigens. Studies include testing of adjuvant candidates with experimental or FDA approved preventative or therapeutic vaccines in relevant animal models to determine the potential efficacy of the vaccine against one or more pathogens relevant to human disease.